Nandita Ganguly Das
`
`Butler University, College of Pharmacy & Health Sciences
`4600 Sunset Avenue, Indianapolis, IN 46208-3485
`
`Overview of Professional Achievements:
`
`Teaching:
`
`0 Fifteen years’ teaching experience in US pharmacy colleges.
`
`317/940-9015
`
`ndas@butler.ec_I_t_i
`
`- Expertise in teaching pharmaceutics (physical pharmacy, pharmaceutical calculations and drug
`
`delivery systems), clinical case studies (at Idaho State University) and elective courses in the
`Pharm.D. curriculum, including co-ordination of team-taught courses.
`
`o Primary personnel involved in the development of the new graduate programs in Drug Delivery at
`
`Idaho State University and Butler University; currently actively involved in the latter.
`
`- Seved as mentor to graduate students in the MS program at Butler University, and to graduate
`students in the MS and PhD programs at Idaho State University.
`o Served as mentor for students in the Research Track Pharm.D. curriculum at Butler University.
`
`0 Served as preceptor for P-4 research rotations for Pharm.D. students, both at Butler University
`
`and Idaho State University.
`
`Research:
`
`- Taught ACPE approved CE lectures to healthcare practitioners at Idaho State University.
`o "Award of Excellence in Scholarship", Butler University COPHS 2006; awarded in part for
`
`Service:
`
`contribution in mentoring faculty colleagues In writing competitive federal grants.
`
`0 Generated NIH competitive
`
`individual
`
`research grant
`
`funding
`
`in
`
`drug targeting and
`
`biopharmaceutics,
`
`in addition to other extramural/intramural research funding at Idaho State
`
`University and Butler University.
`0 Generated NSF funding for purchase of large research equipment (EPSCoR, Idaho).
`
`- Generated intramural
`
`instrument
`
`funds at Butler University to support
`
`translational and
`
`collaborative projects between the graduate and undergraduate laboratory programs.
`
`o Resurrected the overall research program in pharmaceutics at Idaho State University.
`o Participated in the restructuring of the research and graduate program in pharmaceutical
`
`sciences at Butler University COPHS, and developed the new Drug Delivery research track.
`
`o Invited Plenary Lecture, "Nanoscience in Medicine”, Annual Meeting of the Idaho Academy of
`Science, March 26, 2004.
`
`o Reviewer of Primary Research Grants for the NIH-CSR study sections on Gene and Drug
`
`Delivery, Biomaterials and SBIR/STTR Study since 2006.
`
`0 Reviewer of large budget NIH Program Grants for the National Institute of Child Health and
`Human Development (NICHD) since 2010.
`
`o Chair of the 2005 ACPE Self-Study Standards for Curriculum, College of Pharmacy, ISU.
`
`0 Developed and implemented the Integrated Pharm.D. curriculum at Idaho State University as a
`member of Curricular Revision and Implementation Task Forces.
`
`c Member of the 2003-05 Lyman Award selection committee, 2008-09 Research and Graduate
`
`Affairs Committee, and 2010-12 Dawson Biotechnology Award Committee (AACP).
`- Co-organizer/moderator of the roundtable session “Graduate Education in Pharmaceutics and
`
`the Future of Academic Phannaceutics” at the 2003 annual AAPS conference in Salt Lake City,
`UT.
`
`o Invited speaker in the AACP Pharmaceutics Section Chairs meeting during the 2002 annual
`AAPS conference in Toronto, Canada.
`
`0 Served on the Idaho State University Curriculum Council 2001—2004.
`- Reviewer of professional journals in Pharmaceutics and Pharmaceutical Education areas.
`
`Mentorshig:
`
`Advisor and collaborator/committee member of graduate and Pharm.D./undergraduate students’
`research projects.
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`2 Of 12
`
`Management:
`
`Increased revenue for a 400+ Rx/day large chain community pharmacy by 14% over two years,
`while reducing employee attrition to negligible levels.
`
`Ed u cation :
`
`Degree
`Ph.D.
`
`M.Pharm.
`
`Year
`University
`Discipline
`1995
`University of Pittsburgh, PA
`Pharmaceutical Sciences (Pharmaceutics)
`Dissertation:
`Characterization of the Kinetics and Mechanism of Solid-State Reactions by Isothermal
`Microcalorimetry
`Advisor: Late Theodore D. Sokoloski, Ph.D. (protege of Late Takeru Higuchi, University of Vwsconsin)
`
`Banaras Hindu University, India
`Pharmacy (Pharmaceutics)
`Thesis:
`/n—vitro and /n-vivo Evaluation of Controlled Release Dosage Forms of Glibenclamide
`Advisor: S. B. Jayaswal, M. Pharm., Ph.D.
`
`1990
`
`B.Pharm.
`
`Pharmacy (2+4 years),1st rank, Gold Medallist
`
`Banaras Hindu University, India
`
`1988
`
`Pharmacist Licensure:
`
`o State of New Jersey (active), # 28R|O25508OO
`
`a State of Florida (inactive), # PS32063
`
`Professional Experience:
`
`0 Associate Professor of Pharmaceutics (tenure track), Butler University, IN
`
`2005 — present
`
`Teaching:
`
`a
`
`Pharm.D. curriculum — Pharmaceutical Calculations (P1 year — sole instructor), Intro to Dosage Forms
`(P1 year — team taught), Advanced Dosage Forms (P2 year — team taught)
`
`o Graduate curriculum — Intro to Pharmaceutical Research, Research Ethics, Preformulation and Product
`
`Development, Biopharmaceutical Analysis, Advanced Drug Delivery; all team-taught courses.
`
`Research projects:
`
`Lymphatic targeted delivery of tamoxifen (Pl, NIH funded, competitive); Sublingual mucoadhesive delivery
`of buprenorphine for the treatment of drug abuse (co-I, NIH funded, competitive); targeted drug delivery for
`cancer chemotherapy, nose-to-brain drug delivery as a route for targeting neurological disorders, and
`siRNA drug delivery.
`
`0 Research Associate Professor, Butler University, IN
`
`2004 — 2005
`
`Primary responsibility was to reform the research infrastructure and graduate program at Butler University
`COPHS.
`Teaching in Pharm.D.
`curriculum included dosage form laboratories and lectures on
`liposome/drug targeting and inhalation technology.
`
`0 Assistant Professor of Pharmaceutics (tenure track), Idaho State University, ID
`
`1998 — 2004
`
`Teaching:
`
`o
`
`Pharm.D. curriculum — Biopharmaceutics (Physicochemical Basis of Drug Action, P1 year); Physical
`Pharmacy and Pharmaceutical Calculations (Pharmaceutics I, P1 year); Parenteral Formulation and
`Administration, and Drug Targeting (Pharmaceutics ll, P2 year); Compounding and Dispensing Laboratory
`(P2 year); Case Studies sequences (P2 year), Nuclear Pharmacy (elective, P1 through P3 years); Early
`Practice Experience in Compounding and Dispensing (P1 year).
`
`- Graduate curriculum — Industrial Pharmacy (every year); Analytical techniques in pharmaceutics and drug
`delivery (includes laboratory experience); Current
`topics in pharmaceutics and drug delivery (every
`semester); Pharmaceutical colloids and interfaces; Pharmaceutical equilibria and mass transport.
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`Research projects:
`
`3 Of 12
`
`Lymphatic targeted delivery of tamoxifen (PI, NIH funded, competitive); Sublingual mucoadhesive delivery
`of buprenorphine for the treatment of drug abuse (co-Pl, NIH funded, competitive); Lipid formulation of
`tamoxifen and its efficacy studies in MCF-7 cells; Sublingual mucoadhesive dosage form of pentoxifylline
`and anti—emetic drugs to study influence on first pass metabolism; Lipid formulation for the reversal of drug
`resistance in cancer chemotherapy (PhRMA competitive funded for undergraduate research); Self-
`emulsifying formulations for beta carotene and paclitaxel (partially funded for undergraduate research by
`NIH BRIN Idaho); Solid and liquid state interactions between drugs and excipients (equipment funded by
`NSF EpSCOR Idaho); Brain delivery of oligonucleotide drugs.
`
`9 Adjunct Assistant Professor of Pharmaceutics, Nova Southeastern University, FL
`
`1997 — 1998
`
`Taught Physical Pharmacy; guest lectured in the Advances in Drug Delivery course and assisted in the
`Compounding Laboratory.
`
`9 Pharmacist, Eckerd Drug Corporation, FL
`
`1995 — 1998
`
`Managed a 400+ Rx/day store and practiced community pharmacy full-time.
`
`o Graduate Scholar and Research Assistant, SmithKline Beecham Pharmaceuticals, PA 1993 — 1995
`(in legal agreement with University of Pittsburgh, PA)
`Established sensitive isothermal microcalorimetric methods to characterize the kinetics and mechanism of
`
`thermodynamic/kinetic phase transition and crystal growth in formulation of a
`solid-state reactions,
`leukotriene receptor antagonist, monitored multi-step dehydration of theophylline monohydrate at ambient
`temperature.
`
`Advisor: Theodore D. Sokoloski, Ph.D., Research Fellow, SmithKline Beecham Pharmaceuticals, PA;
`
`Retired Professor of Pharmaceutics, Ohio State University.
`
`0 Research Intern; SmithKline Beecham Pharmaceuticals, PA
`
`Summer 1993
`
`Studied effect of moisture on solid-state stability of three leukotriene receptor antagonists using the
`techniques of thermal analysis, SEM and moisture analysis. Advisor: Theodore D. Sokoloski, Ph.D.
`
`0 Graduate ScholarITeaching Assistant; University of Pittsburgh, PA
`
`1990 -1993
`
`Research: Enhanced the dissolution of poorly soluble anti—cancer agent Camptothecin by formulating
`submicron emulsions and characterized the dependence of droplet
`radii on formulation variables in
`microemulsions by laser light scattering technique.
`
`Advisor: Shawn L. Silvestri, Ph.D., Abbott Laboratories, IL (current affiliation).
`
`Teaching: Assisted Pharmacokinetics, Dosage Design I & II and Compounding lab courses
`
`0
`
`Junior Research Fellow, Banaras Hindu University, India
`
`1988 -1990
`
`Formulated and studied polymer microcapsules of glyburide for controlled drug delivery in the management
`of diabetes.
`
`Awards and Honors:
`
`Board of Visitors “Award of Excellence in Scholarship”, Butler University COPHS, 2006
`o
`- Banaras Hindu University Gold Medal for University First rank in B.Pharm., 1988
`-
`Indian Pharmaceutical Association Award for State First rank in B.Pharm., 1988
`
`- G.P. Nair Award for top-ranking pharmacy students in India, Indian Drug Manufacturers’ Association, 1988
`
`Fellowshipsl Scholarships:
`
`- Graduate Teaching Assistantship, University of Pittsburgh, PA, 1990-93
`o
`Junior Research Fellowship, University Grants Commission, India, 1988-90
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae - Nandita G. Das
`
`4 of 12
`
`o Undergraduate Merit Scholarship, University Grants Commission, India, 1985-88
`
`Biographical Recognition:
`
`Invited Presentations:
`
`Who's Who In America, 63"’ ed., Marquis Who's Who, NJ, 2009
`Who's Who Among America's Teachers, 8"‘ ed., 2004
`Who's Who Among America's Teachers, 7"‘ ed., 2003
`
`0
`
`Plenary Lecture, “Nanoscience in Medicine”, Annual Meeting of the Idaho Academy of Science,
`March 26, 2004
`
`o Moderator at the roundtable session on “Graduate Education in Pharmaceutics and the Future of Academic
`
`Pharmaceutics", Annual Meeting of American Association of Pharmaceutical Scientists, October 2003
`
`o
`
`o
`
`impact", Continuing Education Program sponsored by the Idaho State
`“Pegylated drugs — Clinical
`University College of Pharmacy, three presentations between April-May, 2003
`
`“Biopharmaceutics in Pharm.D. Curriculum, When, Where and Why?”, at AACP Pharmaceutics Chairs’
`Meeting, Annual Meeting of American Association of Pharmaceutical Scientists, November 2002
`
`Memberships of:
`Professional Societies
`
`American Association of Pharmaceutical Scientists (AAPS)
`American Association of Colleges of Pharmacy (AACP)
`
`Committees:
`
`Butler University: Dept Chair Search Committee (2009-10), Holcomb Research Award Committee (Fall
`2004), Student Affairs Committee (COPHS 2004-5). Research & Graduate Review Committee (COPHS 2004-
`present),
`Institutional Animal Care and Use Committee (2005-present), Educational Resources Committee
`(COPHS 2005-present), Organic Chemistry Faculty Search Committee (2005-6)
`
`(2000-2004), Faculty
`(2002-2004), Cultural Affairs Council
`Idaho State University: Curriculum Council
`Research Committee (1999), Women's History Month Celebration Planning Committee (2003-2004)
`
`College of Pharmacy, Idaho State University: Chair of the 2005 ACPE Self-Study Standards for Curriculum,
`Curricular Affairs (2001-2004), Curriculum Implementation Task Force (2001-2003), Curriculum Revision Task
`Force (1999-2000), Student Affairs (1999)
`
`City of Pocatello: Member, Human Relations Advisory Committee, City of Pocatello, ID 2003-2004
`
`Indian Students’ Association (1991-1993); Member, Organizing
`President,
`University of Pittsburgh:
`Committee, 1991 Annual Meeting of the Association of Graduate Students in Pharmaceutical Sciences
`(GRASP)
`
`Journal Reviewer:
`o
`Pharmaceutical Research
`o
`Journal of Controlled Release
`o American Journal of Pharmaceutical Education
`
`a Drug Development & Industrial Pharmacy
`.
`JAPhA
`
`
`FUNDED GRANTS
`
`Extramural:
`
`Haslanger, MF, (PI - Apex Therapeutics, lnc.), Kelley M, (Co-I- IUPUI), Das SK. (Collaborator), Das NG.
`
`(Collaborator), Redox protein APE1/REF-1 as a target for age-related macular degenration (AMD),
`
`(1 R41 EY019784-01), September 2009 - September 2010
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`5 Of 72
`
`Das NG (PI), Das SK (Co-I), Wilson CM (Collaborator), Lymphatic targeted tamoxifen for breast cancer
`
`therapy,
`
`(1R15 GM068439—01), NIH — National
`
`Institute of General Medical Sciences, August 2003
`
`—July 2005; no cost extension through March 2007
`
`Das SK (Pl), Das NG (Co-I), Mucoadhesive buprenorphine for opioid addiction therapy NIH — National
`Institute on Drug Abuse (1R15DA015358~01, 5R15DA015358-02), August 2002-July 2004, no—cost
`
`extension through July 2006
`
`Das SK (PI), Das NG (Collaborator), Surface modified nanoemulsions for reversal of multidrug resistance
`
`in cancer chemotherapy, PDA Foundation for Pharmaceutical Sciences, 04/01/2001-03/31/2002
`
`Das NG (PI), Young faculty start-up grant for equipment (Modu|ated® Differential Scanning Calorimeter),
`
`National Science Foundation — EPSCoR, July 01, 1999—June 30, 2000
`
`Das NG (Pl), Das SK (Collaborator), Nanoemulsion delivery system for poorly soluble antineoplastic
`
`agents, Pharmaceutical Research and Manufacturers of America Foundation,
`
`January 01, 2000
`
`—December 31, 2000
`
`Intramural:
`
`Cich K, Evaluating the Effect of a Cyclosporine Emulsion Formulation on Reversal of Resistance in the
`
`Multi-drug Resistant Cancer Cell Line MES-SA—Dx5 using P-gp Functional Assays, Butler USRP Fairbanks
`
`Scholar August 2010 — July 2011 (Faculty Mentor Das, NG)
`
`Cich K, P-gp functional studies to evaluate the effect of cyclosporine emulsion formulation on reversal of
`
`resistance in the multi drug resistant cancer cell line MES-SA—Dx5, Butler Summer Institute 2009 (Faculty
`
`Mentor, Das, NG)
`
`Das NG (PI), Development of multi-component sub micron emulsions for delivery of doxorubicin and
`
`evaluation of cell survival
`
`in the multi drug resistant cell
`
`line MES-SA—Dx5, Butler Holcomb Research
`
`Award, June 2008 — May 2009
`
`Das NG (PI) and Peak A, lnsulin Stability at Room Temperature: A Six Month Assessment, Butler Holcomb
`
`Research Award, June 2007 — May 2008
`
`Das NG (PI), Lipid mediated delivery of siRNA, Butler Holcomb Research Award, June 2006 — May 2007
`
`Borchert SD, Das NG (PI), pH dependent stability of hyaluronidase, Undergraduate Research Committee,
`
`Idaho State University, 04/30/2001-03/31/2002
`
`Das NG (Pl), Das SK (Co—l), HPLC equipment for analysis of drugs, University Research Committee, Idaho
`
`State University, July 01, 2000-June 30, 2001
`
`Das NG (PI), Evaluation of Mucoadhesive Performance of Polymer Compacts in Sublingual Drug Delivery,
`
`University Research Committee, Idaho State University, 2002-2003
`
`Das SK (PI), Das NG (Co-I), Equipment for development of microemulsion for enhancing the bioavailability
`
`of poorly soluble drugs, University Research Committee, Idaho State University, July 01, 1999-June 30,
`2000
`
`Kuzmic B, Das NG (PI), Sublingual delivery system of promethazine for therapy of morning sickness in
`
`pregnancy, Undergraduate Research Committee, Idaho State University, 2003
`
`Faculty mentor for BRIN summer project “Novel self—emulsifying delivery system for targeted lymphatic
`
`delivery of beta-carotene”, funded by NlH—BR|N for Sherry Borchert, Pharm.D.
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae —— Nandita G. Das
`
`6of12
`
`Mentoring Experience:
`
`Post doctoral fellows
`Name
`
`Prabhakar Veerareddy, Ph.D.
`
`Vijay K. Sutaria, Ph.D.
`
`Graduate students
`
`Duration
`10/O5 - 9/06
`
`4/07 - 5/O8
`
`Name
`Swathi Pinnanameni
`
`Degree
`MS
`
`Duration
`
`Fa||'99 - spring'02
`
`Madhu Surapaneni
`
`MS
`
`Fa||'O1 - Spring'04
`
`My role
`Advisor
`
`Advisor
`
`My role
`Committee
`member
`
`Advisor
`
`Kanako Somatsu
`
`MS
`
`Fall '05 - Summer '07
`
`Advisor
`
`Current Affiliation
`
`Principal, St Peters Institute of
`Pharm Sci, Warangal, INDIA
`Assistant Prof. of Pharmaceutics
`
`University of South Florida
`
`Current Affiliation
`Senior Scientist,
`Bristol-Myers Squibb,NJ
`
`Project Manegement
`Bristol-Meyers Squibb, NJ
`
`Market Research Scientist
`
`Boston Scientific, Japan
`
`Sharmeen Rafique
`
`Amit Kumar
`
`Sheetal D'Me|lo
`
`Ruchi Kapoor
`
`Satwati Shukla
`
`MS
`
`MS
`
`MS
`
`MS
`
`MS
`
`Spring '06 - Spring '08 Advisor
`
`CEO, Laminos Laboratories, India
`
`Spring '07 - Spring '09 Advisor
`
`Scientist, QS1 Pharmaceuticals
`
`Fa||‘06 - Spring'O9
`
`Committee
`member
`
`PhD student in Pharmaceutics
`University of Iowa
`
`Fa||'O7 - Fall'1O
`
`Advisor
`
`Senior Associate Scientist
`
`Fal|‘08 - Summer'1O
`
`Advisor
`
`Novartis Biotech, Emeryville, CA
`Housewife
`
`Jainik Panchal
`
`MS candidate
`
`Fa||'09 - summer'11
`
`Advisor
`
`Neelima Mantha
`
`MS candidate
`
`Fall‘O9 - Fa||'11
`
`Advisor
`
`PhD student in pharmaceutics
`Purdue University
`
`Yatri Patel
`
`MS candidate
`
`Fa||‘O9 - Fa|l'11
`
`Shounak Bose
`
`MS candidate
`
`Fa|l'O9 - Fa||'11
`
`Committee
`member
`
`Committee
`member
`
`Advisor
`
`Committee
`member
`
`Advisor
`
`Committee
`Member
`Advisor
`Committee
`member
`
`MS student
`
`MS student
`
`MS student
`
`MS student
`
`MS student
`MS student
`
`Fa||'1O -
`
`Fa||'1O -
`
`Fa||"i1 -
`
`Fa||'11 -
`
`Fa||’1 3 -
`Fa||’1 3 -
`
`Rameez Kagdi
`
`Puja Kanvinde
`
`Sanika Rege
`
`Arpita Mitra
`
`Rukmini Ladi
`Nikeeta Kheradia
`
`Professional students
`
`Name
`
`Jerry Holland (PhRMA grant)
`
`Sherry Borchert (ISU UgRC grant) PharmD
`PharmD
`
`Brenik Kuzmic (ISU UgRC grant)
`Susan Surber
`
`Degree
`PharmD
`
`My role
`
`Advisor
`
`Advisor
`
`Advisor
`
`PharmD
`
`Advisor
`
`Current Affiliation
`
`Retail pharmacist
`
`Pharmacy owner in CA
`
`Retail pharmacist
`Pharmacist
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`7 of 12
`
`Brenda Greene
`
`PharmD
`
`Advisor
`
`Pharmacist
`
`Katie Cich (Wa|mart scholar)
`
`PharmD candidate
`
`Advisor
`
`Staff Pharmcist, U of FL
`
`Precegtor for P4 research rotations:
`
`Name
`
`Peter V\fi||eitner (ISU)
`
`Sherry Borchert (ISU)
`
`Samreen Khatri (Butler)
`
`Katie Cich (Butler)
`
`Qa_gr<a_e
`
`PharmD
`
`PharmD
`
`PharmD
`
`_My_r9_|e
`
`Current Affiliation
`
`Preoeptorladvisor Retail pharmacist
`
`Preceptor/advisor Pharmacy owner in CA
`
`Preoeptor/advisorstaff VA Pharmacist
`
`PharmD candidate
`
`Preceptor/advisorStaff Pharmcist, U of FL
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`PUBLICATIONS
`
`Research journal articles:
`
`8of12
`
`1.
`
`R. Ladi, S. K. Das and N. G. Das, Nanomedicine for neurodegenerative diseases,
`Pharmaceutical Nanotechnology (submitted)
`
`invited review in
`
`S. R. D’mel|o, N. G. Das, V. B.. Sutariya and S. K. Das, Optimized paclitaxel and cyclosporine A loaded
`nanoparticles of PEG-PLGA for reversal of multidrug resistance in MES-SA/Dx5 cervical cancer cells,
`(submitted)
`
`V. B. Sutariya, N. G. Das and S. K. Das Lymphatic Targeted Oral Drug Delivery: Challenges and
`Opportunities, (submitted)
`
`S. Khatri, N. G. Das and S. K. Das, Effect of methotrexate conjugated PAMAM dendrimers on the viability
`of MES-SA uterine cancer cells, J. Phar. Bioall. Sci., 6, 297-302, 2014
`PMID: 25400413
`
`N. Mantha, S. K. Das and N. G. Das, Recent trends in detection of Huntingtin and preclinical models of
`Huntington's
`disease,
`ISRN Molecular
`Biology,
`Article
`ID
`190976,
`5
`pages,
`2014
`http://dx.doi.org/10.1155/2014/190976
`
`Sherry, D. B., Peter, G. W., & Nandita, G. D., An Overview of Drugs used in the Treatment of Addiction.
`Indian Journal of Pharmacy Practice, 5(4), 21-27, 2012
`
`S. N. Sani, N. G. Das and S. K. Das, Effect of microfluidization parameters on the physical properties of
`PEG-PLGA prepared using high pressure microfluidization, J Microencap., 26 (6), 556-561, 2009
`
`M. S. Surapaneni, S. K. Das and N. G. Das, Effect of excipient and processing variables on adhesive
`properties and release profile of pentoxifylline from mucoadhesive tablets, Drug Development & industrial
`Pharmacy, 32 (3), 377-387, 2006
`
`N. G. Das and S. K. Das, Development of mucoadhesive dosage forms of buprenorphlne for sublingual
`delivery, Drug Delivery-- The Journal of Delivery and Targeting of Therapeutic Agents, 11, 1-7, 2004
`
`J. Franckum, D. Ramsay, N. G. Das, S. K. Das, Pluronic Lecithin Organogel (PLO) for local delivery of anti-
`inflammatory drugs, lntemational Journal of Pharmaceutical Compounding, 8 (2), 101-105, 2004
`
`S. Pinnamanenl, N. G. Das and S. K. Das, Comparison of oil-in-water emulsions manufactured by
`microfluidization and homogenization, Die Pharmazie, 58, 554-558, 2003
`
`N. G. Das and S. K. Das, An approach to pharmaceutics course development as the profession changes in
`the 215‘ century, Pharmacy Education, 1, 159-171, 2002
`
`S. Pinnamanenl, N. G. Das and S. K. Das, Formulation approaches for orally administered poorly soluble
`drugs, “'9 Pharmazie, 57, 291-300, 2002
`
`S. K. Das and N. G. Das, Preparation and in vitro dissolution profile of dual polymer (EUDRAGlT"" RS100
`and RL100) microparticles of diltiazem hydrochloride, Journal of Microencapsulation, 15, 445-452, 1998
`
`S. P. Duddu, N. G. Das, T. P. Kelly and T. D. Sokoloski, Microcalorimetric investigation of phase
`transitions:
`I. Is water desorption from theophylline.HOH a single step process? International Journal of
`Phannaceutics, 114, 247-256, 1995
`
`l. G. Tucker, D J. T. Hill and N. Ganguly, Evaluation of poly (isobutylcyanoacrylate)
`S. K. Das,
`nanoparticles for mucoadhesive ocular drug delivery. I - Effect of formulation variables on physicochemical
`characteristics of nanoparticles, Pharmaceutical Research, 12, 534-540, 1995
`
`S. Silvestri, N. Ganguly and E. Tabibi, Predicting the effect of nonionic surfactants on dispersed droplet
`radii in submicron oil in water emulsions, Pharmaceutical Research, 9, 1347-1350, 1992
`
`N. Ganguly, S. B. Jayaswal, J. Singh and M. M. Varma, Controlled release dosage forms of glibenclamide,
`Eastern Pharmacist, 35 (9), 117-118, 1992
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18.
`
`Patent
`
`N.
`
`G. Das, M. S. Surapaneni, S. K. Das, Dissolution testing of solid dosage forms intended to be administered
`in the oral cavity, United States Patent # 7,331,251, issued on February 19, 2008
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`Books and Book Chapters (Peer-reviewed)
`
`90f12
`
`1 .
`
`2.
`
`S. A. Rege, S. K. Das and N. G. Das, Biodegradable polymeric carriers for siRNA delivery, in Bio—Targets &
`Drug Delivery Approaches (2016)
`N. G. Das, Paracitides,
`in Loyd. V. Allen ed., Remington's Practice of Pharmacy & Pharmaceutical
`Sciences, 22nd ed, 2012
`
`S. R. D'Mello, N. G. Das, S. K. Das, Polymeric Nanoparticles for Small Molecule Drugs: Biodegradation of
`polymers and fabrication of nanoparticles,
`in Y. Pathak and D. Thassu ed., Drug Delivery nanoparticles
`Formulation and Characterization, lnforma Healthcare, NY, 2009, chapter 2, pp.16-34
`
`M. Kothuri, S. Pinnamaneni, N. G. Das and S. K. Das, Microparticles and nanoparticles for ocular drug
`delivery, in A. K. Mitra, (ed), Ocular Drug Delivery Systems, 2”“ ed., Marcel Dekker, NY, 2003, pp. 437-466
`
`Professional Articles (non-peer reviewed)
`1 . N. G. Das and S. K. Das, Formulation of poorly soluble drugs, Drug Delivery Report, Spring/Summer 2006,
`Pharma Ventures
`
`2. N. G. Das and S. K. Das, Controlled-release of oral dosage forms, Formulation, Fill & Finish — A
`Technology Primer 2003, supplement to Pharmaceutical Technology, 27 (6), June 2003, pp.10-16
`
`Conference Proceedings (peer reviewed)
`1. S. K. Das, R. M. Kagdi, and N. G. Das, Knockdown of Survivin Protein Expression Using Llposomal
`siRNA, 39th Annual Meeting & Exposition of the Controlled Release Society, # 259, Quebec City, Canada,
`July 2012
`
`N. G. Das, S. Rafique and S. K. Das, Cell Survival Studies in Multi-Drug Resistant MES-SA/Dx5 Cells
`Traerted with Submicron Emusion Formulations of Doxorubicin, with or without Cyclosporin A, 35"’ Annual
`Meeting & Exposition of the Controlled Release Society, New York, NY, July 2008
`
`N. G. Das, B. L. Greenen and S. K. Das, In Vitro Dissolution of Buprenorphine Sublingual Tablets Using a
`Novel Flow-Through Apparatus, Transactions of 32nd Annual Meeting and Exposition of the Controlled
`Release Society, Vienna, Austria, 2006
`
`P. R. VeeraReddy, N. G. Das and S. K. Das, Evaluation of In Vitro Swelling and Mucoadhesive Properties
`of Carbomer and Hydroxypropyl Methyl Cellulose Containing Sublingual Tablets, Transactions of 32nd
`Annual Meeting and Exposition of the Controlled Release Society, Vienna, Austria, 2006
`
`N. G. Das and S. K. Das, Development and in vitro evaluation of self-assembling submicron emulsion
`system for lymphatic targeting of tamoxifen, Transactions of Annual Meeting of Controlled Release
`Society, 31, 2004
`
`S. K. Das and N. G. Das, Development of Mucoadhesive Sublingual Delivery System for Buprenorphine,
`Transactions of Annual Meeting of Controlled Release Society, 31, 2004
`
`Conference Abstracts (peer reviewed)
`1 .
`
`R. Kammari, N. G. Das and S. K. Das, Co—de|ivery of Paclitaxel and Survivin siRNA Using iRGD Peptide
`Conjugated PLGA Nanoparticles, Annual Meeting of American Association of Pharmaceutical Scientists,
`San Diego, CA, November 2014
`
`S. Rege, N. G. Das and S. K. Das, Enhanced cytotoxicity via downregulation of surviving expression in
`MCF-7 cells by PLGA-siRNA nanoparticles, Annual Meeting of American Association of Pharmaceutical
`Scientists, San Antonio, TX, November 2013
`
`P. Kanvinde, N. G. Das and S. K. Das, Development of iRGD peptide modified polymeric docetaxel
`nanoparticles targeted to integrin-overexpressing breast cancer cells, Annual Meeting of American
`Association of Pharmaceutical Scientists, Chicago, IL, October 2012
`
`S. Bose, N. G. Das and S. K. Das, Topical ocular formulation of a poorly soluble and poorly permeable
`experimental drug for the treatment of macular degeneration, Annual Meeting of American Association of
`Pharmaceutical Scientists, Washington, DC, October 2011
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Curriculum vitae — Nandita G. Das
`
`10 of 12
`
`5.
`
`Y. Patel, N. G. Das and S. K. Das, Development of docetaxel loaded polymeric nanoparticles conjugated
`with an aptamer targeted to breast cancer cells, AAPS - National Biotechnology Conference, San
`Francisco, May, 2011, AAPS-Amgen Travel Award for Patel
`
`N. Mantha, N. G. Das and S. K. Das, Inhibition of mutant Huntingtin with liposomal siRNA in an inducible
`PC-12 cell
`line, AAPS - National Biotechnology Conference, San Francisco, May, 2011, AAPS-Amgen
`Travel Award for Mantha
`
`S. L. Shukla, J. Panchal, S. K. Das, N. G. Das, Development of Liposomes and Polymer Nanoparticles for
`Tumor Targeting of the Anti-Angiogenic Drug Sunitinib, Annual Meeting of FlP & American Association of
`Pharmaceutical Scientists, New Orleans, November, 2010
`
`R. P. Kapoor, S. K. Das and N. G. Das, Development of Multicomponent Submicron Emulsions and their
`Efficacy in Delivering Vincristine to Multidrug Resistant MES-SA/Dx5 cells, Annual Meeting of American
`Association of Pharmaceutical Scientists, Los Angeles, CA, November, 2009, AAPS-AstraZeneca Travel
`Award for Kapoor
`
`S. L. Shukla, N. G. Das and S. K. Das, Development of Self Emulsifying Nanoemulsions of the Anti-
`Angiogenic Agent Sunitinib, Annual Meeting of American Association of Pharmaceutical Scientists, Los
`Angeles, CA, November, 2009
`
`S. R. D'mello, N. G. Das, S. K. Das, Efficacy Study of Paclitaxel Loaded PEG—PLGA Nanoparticles in
`Multidrug Resistant MES-SA/Dx5 Cancer Cells, Annual Meeting
`of American Association
`of
`Pharmaceutical Scientists, Atlanta, GA, November, 2008
`
`R. P. Kapoor, S. Rafique, S. K. Das, N. G. Das, Multicomponent Submicron Emulsions for Delivery of
`Vincristine and Evaluation of its Efficacy in the Multidrug Resistant Cell Line MES-SA/Dx5, Annual Meeting
`of American Association of Pharmaceutical Scientists, Atlanta, GA, November, 2008
`
`A. Kumar, S. K. Das, V. B. Sutariya, N. G. Das, Development and Evaluation of Thermoreversible Gels for
`Nasal Delivery of Troglitazone, Annual Meeting of American Association of Pharmaceutical Scientists,
`Atlanta, GA, November, 2008
`
`V. B. Sutariya, N. G. Das and S. K. Das, Tamoxifen Loaded Self-Nanoemulsifying Drug Delivery System for
`lntestinal Lymphatic Transport: Development
`and Characterization, AAPS-National Biotechnology
`Conference, Toronto, Canada, June 2008; *** Coverage in AAPS Press Release and AAPS Travel
`Award for Sutariya
`
`S. Khatri, N. G. Das and S. K. Das, Evaluation of the efficacy of methotrexate-dendritic nanodevices using
`cell survival studies in MES-SA cells, Annual Meeting of American Association of Pharmaceutical
`Scientists, San Diego, CA, November 2007
`
`S. Rafique, S. K. Das, S. D’Mello and N. G. Das, Development of multi-component submicron emulsions
`for delivery of doxorubicin and evaluation of cell survival in multi-drug resistant cell line CRL-1977, Annual
`Meeting of American Association of Pharmaceutical Scientists, San Diego, CA, November 2007
`
`S. D’Mello, N. G. Das and S. K. Das, Development of PLGA-PEG nanoparticles of paclitaxel and
`evaluation of cell survival
`in CRL-1976 cancer cells, Annual Meeting of American Association of
`Pharmaceutical Scientists, San Diego, CA, November 2007 AAPS - AstraZeneca Travel Award for
`D’Mello
`
`K. Somatsu, N. G. Das and S. K. Das, Optimization of liposomal siRNA delivery in HeLa cells, National
`Biotechnology Conference, San Diego, CA, June, 2007
`
`P. R. Veerareddy, N. G. Das and S. K. Das, Effect of processing parameters on the particle size of solid
`lipid nanoparticles, Annual Meeting of American Association of Pharmaceutical Scientists, San Antonio, 7X
`November 2006
`
`P. R. Veerareddy, S. K. Das and N. G. Das, Formulation of tamoxifen loaded solid lipid nanoparticles,
`Annual Meeting of American Association of Pharmaceutical Scientists, San Antonio, 7X, November 2006
`
`K. Somatsu, J. V. Ludlow, S. K. Das, and N. G. Das, Establishment of siRNA transfection in HeLa cells for
`knockdown of Presenilin-1, Meeting of American Association of Pharmaceutical Scientists, San Antonio,
`7X, November 2006
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18.
`
`19.
`
`20.
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`TEVA EXHIBIT 1047
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Cuniculum vitae — Nandita G. Das
`
`11 of 12
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`38.
`
`J. V. Ludlow, N. G. Das and S. K. Das, Validation of a fluorescence HPLC analytical method for
`buprenorphine hydrochloride, Meeting of American Association of Pharmaceutical Scientists, San Antonio,
`TX November 2006
`
`N. G. Das, J. Ludlow, S. K. Das, Self-emulsifying mono-, di- and triglyceride formulations for lymphatic
`delivery, Annual Meeting of American Association of Pharmaceutical Scientists, Nashville, TN, November
`2005
`
`S. Khatri, J. V. Ludlow, N. G. Das and S. K. Das, Stabilization of ovalbumin in nanoparticles, Pfizer
`Undergraduate Research Symposium, Groton, CT, September 2005
`
`N. G. Das, M. S. Surapaneni, L. Aburto, S. Sorensen and S. K. Das, Development and characterization of
`matrix-type mucoadhesive tablets of buprenorphine for sublingual delivery, Annual Meeting of American
`Association of Pharmaceutical Scientists, Baltimore, MD, November 2004
`
`N. G. Das and S. K. Das, Development of self-emulsifying formulations for lymphatic targeting of
`Tamoxifen, Annual Meeting of American Association of Pharmaceutical Scientists, Baltimore, MD,
`November2004
`
`A. W. Morgan, N. G. Das and S. K. Das, Development of poly (lactide-co-glycolide